Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$473.69 USD
-7.04 (-1.46%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $473.68 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 121 - 140 ( 329 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: November 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Trikafta FDA Approval and NHS England Agreement Present the Quarter With a Hammer
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2019: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond CF, Pipeline Advancement Continues in AATD and APOL1 Kidney Disease; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Alpha-1 KOL Offers Perspective on Current AATD Approaches and VX-814, Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
KOL Reception and Dinner on Alpha-1 Antitrypsin Deficiency (AATD)
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Adds Targeted Protein Degradation Expertise to Developmental Arsenal; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond Cystic Fibrosis: Thoughts Around AATD Therapy Development; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A